Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00119691 · ClinicalTrials.gov registry record · Phase 2

Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction

A Phase 2 study, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 2
Development phase
34
Enrollment target

NCT00119691: Completed Phase 2 study, sponsored by Brigham and Women's Hospital.

NCT00119691 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00119691, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 2
Development phase
34 participants
Enrollment target

Study Summary

The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.

Interventions

  • DRUG Nesiritide

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2003-04
Est. Completion 2005-11
Phase Phase 2
Brigham and Women's Hospital

937 total trials

What the finished NCT00119691 record still lists

NCT00119691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).

The record links to 0 conditions, and to 1 intervention - of which Nesiritide is the first listed.

NCT00119691 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00119691 about?

NCT00119691 is a clinical study titled "Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction". The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.

What is the current status of trial NCT00119691?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2003-04. Estimated completion is 2005-11.

What interventions are being tested in trial NCT00119691?

The interventions under investigation include: Nesiritide (DRUG).

Who is sponsoring clinical trial NCT00119691?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00119691's enrollment target sits among peer trials

34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00119691, the US trial registry maintained by the National Library of Medicine. NCT00119691 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.